Retatrutide Dosage Chart
The trial titration (up to 12mg), plus dose-to-units
Retatrutide ("Reta") is investigational, so there is no FDA-approved dosing schedule. The TRIUMPH Phase 3 program escalated weekly toward 8–12mg over several months. This chart summarizes that trial titration and converts each dose to syringe units for reference only — it is not medical advice.
How retatrutide was titrated in trials
Retatrutide is a once-weekly injection that, in the TRIUMPH Phase 3 program, was escalated slowly to limit nausea — starting low and stepping up roughly every 4 weeks toward maintenance doses of 8mg or 12mg. The highest 12mg dose produced the deepest weight loss but also the most gastrointestinal side effects.
Because retatrutide is not approved, there is no official dosing chart. The schedule below reflects the trial titration and is provided for educational reference, not as a protocol to follow.
Retatrutide trial titration (toward 8–12mg)
| Dose | Typical timing | Purpose |
|---|---|---|
| 2 mg | Weeks 1–4 | Starter / tolerance doseBest |
| 4 mg | Weeks 5–8 | First step-up |
| 6 mg | Weeks 9–12 | Continued escalation |
| 8 mg | Weeks 13–16 | Maintenance option |
| 12 mg | Week 17+ | Highest studied maintenance dose |
Retatrutide dose to syringe units (vials)
| Dose | 5 mg/mL | 10 mg/mL | 15 mg/mL |
|---|---|---|---|
| 2 mg | 0.4 mL → 40 | 0.2 mL → 20 | 0.13 mL → 13Best |
| 4 mg | 0.8 mL → 80 | 0.4 mL → 40 | 0.27 mL → 27 |
| 6 mg | 1.2 mL → 120* | 0.6 mL → 60 | 0.4 mL → 40 |
| 8 mg | 1.6 mL → 160* | 0.8 mL → 80 | 0.53 mL → 53 |
| 12 mg | 2.4 mL → 240* | 1.2 mL → 120* | 0.8 mL → 80 |
Safety & context
Higher retatrutide doses delivered more weight loss but more nausea, vomiting, and discontinuations in trials, which is why escalation is slow. There is no established "right" dose outside the trial protocols.
This page is an educational reference about how retatrutide was dosed in studies. It is not a recommendation to use an unapproved drug; decisions belong with a qualified healthcare professional.
Guide FAQs
There is no FDA-approved retatrutide dose because it is investigational. In the TRIUMPH Phase 3 program it was escalated weekly toward maintenance doses of 8mg or 12mg, with 12mg producing the deepest weight loss.
In trials it started low (around 2mg) and increased roughly every 4 weeks toward 8–12mg, slowly, to limit nausea. Exact steps varied by trial arm. This is not an approved schedule.
For vials, units depend on concentration. At 10mg/mL: 2mg = 20 units, 4mg = 40, 8mg = 80, 12mg = 120. Use the reconstitution calculator to set a concentration that keeps your dose under a full syringe.
No. As of 2026 retatrutide is investigational and not FDA approved. This chart reflects trial dosing for educational reference only.
Yes. Shotlee logs each weekly dose, side effects, and weight, and reminds you when to escalate — free.
Track Your Retatrutide Protocol in Shotlee
Log doses, get escalation reminders, and track side effects and weight — free.